Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Cachexia; Cancer; Sarcopenia

In brief

Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.

Key facts

Study ID

NCT07519837

Run by

China Medical University, China

People needed

1000

Starts

2026-03-18

Expected to finish

2028-03-20

Last updated by the study team

2026-04-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Signed informed consent form and voluntary participation in this study
• Histologically and/or cytologically confirmed diagnosis of cancer
• Patients with gastrointestinal malignancies, including:
• Esophageal cancer
• Hepatocellular carcinoma
• Gastric cancer
• Cholangiocarcinoma
• Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy

You may not qualify if…

• Pregnant or lactating women
• Presence of contraindications to surgery
• Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
• Presence of two or more concurrent primary tumors

Where it is running

• The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.